These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 21269503)

  • 1. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
    Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
    BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis.
    Ditkowsky JB; Schwartzman K
    PLoS One; 2014; 9(1):e83526. PubMed ID: 24454706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
    Fu H; Lin HH; Hallett TB; Arinaminpathy N
    Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
    Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
    Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality.
    Harris RC; Dodd PJ; White RG
    BMC Med; 2016 Sep; 14(1):138. PubMed ID: 27633883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
    Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
    Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of universal BCG vaccination of Japanese infants.
    Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
    Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland.
    Sweeney E; Dahly D; Seddiq N; Corcoran G; Horgan M; Sadlier C
    BMC Infect Dis; 2019 May; 19(1):397. PubMed ID: 31072396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
    Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
    Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term health and economic benefits of DOTS implementation in Ecuador.
    Oxlade O; Vaca J; Romero E; Schwartzman K; Graham B; Hernandez L; Tannenbaum T; Menzies D
    Can J Public Health; 2006; 97(1):14-9. PubMed ID: 16512320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis vaccine: A journey from BCG to present.
    Fatima S; Kumari A; Das G; Dwivedi VP
    Life Sci; 2020 Jul; 252():117594. PubMed ID: 32305522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
    Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
    PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
    Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
    Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NATCON 2022 Panel discussion: "TB vaccination - Going Forward".
    Banurekha VV; Padmapriyadarsini C; Bhargava S; Sachdeva K
    Indian J Tuberc; 2023 Jul; 70(3):366-369. PubMed ID: 37562914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
    Tameris M; Geldenhuys H; Luabeya AK; Smit E; Hughes JE; Vermaak S; Hanekom WA; Hatherill M; Mahomed H; McShane H; Scriba TJ
    PLoS One; 2014; 9(2):e87340. PubMed ID: 24498312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's Old and New in Tuberculosis Vaccines for Children.
    Cranmer LM; Cotton MF; Day CL; Nemes E
    J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S110-S116. PubMed ID: 36314550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis vaccine.
    Sarhan MA
    Saudi Med J; 2010 Jan; 31(1):9-13. PubMed ID: 20062891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
    Dye C
    J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.